At the heart of the initiative are new International Adaptations of the NCCN Clinical Practice Guidelines in Oncology, a family of treatment recommendations widely regarded as among the most thorough and frequently updated clinical standards in medicine. The Philippine adaptations are being developed in close collaboration with the Philippine Society of Medical Oncology and, for gynecologic malignancies, with the Society of Gynecological Oncologists of the Philippines, with additional support from the International Gynecologic Cancer Society. The planned disease coverage is broad and deliberately aligned with the country’s most pressing cancer burdens: B-cell lymphomas, breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, prostate cancer, and rectal cancer will be adapted with PSMO, while cervical, ovarian, and uterine cancers will be adapted with SGOP and IGCS. Once completed, all of the NCCN Guidelines for the Philippines will be available free of charge through the network’s global portal in the months ahead.

Crystal S. Denlinger, MD, Chief Executive Officer of NCCN, framed the collaboration as part of a broader commitment to equity in cancer care. “Our joint efforts in the Philippines and beyond reflect a shared commitment to improving access to appropriate cancer care, reducing disparities in treatment, and strengthening oncology practice through proven guidance,” she said. “By working with regional experts to regionally tailor NCCN’s guidelines for use in the Philippines, we combine our expertise to provide evidence-based recommendations that are more meaningful and usable for regional clinical settings. Through this global collaboration, we will create opportunities to grow our efforts with providers worldwide to develop practical tools that serve communities across the globe.”

The technical logic behind international adaptations is straightforward but demanding. Clinical guidelines encode not only biomedical evidence but also assumptions about available diagnostics, drug formularies, referral pathways, regulatory approvals, and health system financing. A recommendation that is feasible at a comprehensive cancer center in the United States may be impractical in a provincial hospital in the Philippines, where imaging capacity, pathology services, or targeted therapies may be limited or differently regulated. Adaptation therefore involves panels of local experts who review each recommendation against the realities of regional practice, adjusting where necessary while preserving the evidence-based core. The result is intended to be a document that clinicians can actually follow, rather than an aspirational standard that sits unused on a shelf.

The Manila summit, held on October 6, went beyond the mechanics of guideline writing to address a harder question: how localized recommendations become embedded in national health policy. PSMO, the Department of Health, and NCCN convened a high-level meeting focused on strategies to integrate the adapted guidelines into national programs under the National Integrated Cancer Control Act, the Philippine legislation that established a coordinated framework for cancer prevention, treatment, and survivorship. Highlighting global implementation models, NCCN was joined by Professor Jacek Jassem of the Medical University of Gdansk, who shared insights from Poland’s successful experience in developing and implementing the NCCN Guidelines for Poland, an example often cited as proof that a national health system can adopt and operationalize adapted guidelines at scale.

For the Philippine Society of Medical Oncology, the project represents a chance to codify local expertise within an internationally trusted framework. “NCCN Guidelines are the most reliable tools that cancer care providers use worldwide to improve prevention, treatment, and outcomes for people with cancer. Developing regionally tailored guidelines alongside NCCN and international experts allows us to seamlessly combine global clinical standards with our local expertise and regulatory environment,” said Hiyasmin A. Alejandro, MD, PSMO Vice President and Co-Lead of the NCCN adaptation project in the Philippines. “This collaboration directly strengthens our medical oncology practice, empowering Filipino healthcare providers to deliver more consistent, high-quality, and equitable care customized to the realities and regulations here in the Philippines.”

The gynecologic cancer component carries particular weight in a country where cervical, ovarian, and uterine malignancies remain significant causes of cancer-related death among women, and where access to subspecialty care varies dramatically between metropolitan Manila and more remote regions. Dr. Doris Benavides, immediate past president of the Society of Gynecological Oncologists of the Philippines, emphasized that adaptation is a two-way process rather than a simple translation exercise. “True collaboration means co-creating solutions that meet the specific needs of our patients,” she said. “By adapting the NCCN Guidelines for cervical, uterine, and ovarian cancers to the Philippine setting, we’re giving our gynecologic oncologists evidence-based recommendations grounded in the realities of local practice in various regions of the country. This important initiative will raise the standard of care and improve long-term health outcomes for Filipino women and their families. We are grateful to NCCN and IGCS for their commitment to global collaboration. This partnership lets Filipino specialists contribute local insight while benefiting from one of the world’s most trusted oncology guideline frameworks.”

The Philippine program is also serving as a template for further expansion. Building on the gynecologic cancer initiative, NCCN recently signed a new Memorandum of Understanding with the International Gynecologic Cancer Society to explore the implementation of tailored gynecologic cancer guidelines in other regions. “IGCS is committed to improving gynecologic cancer care worldwide through education, training, and awareness,” said Mary Eiken, MS, CEO of IGCS. “Our Strategic Alliance Partner Program brings together leaders and members of gynecologic oncology organizations across specialties and regions around the world. We’re excited to collaborate with NCCN to help translate NCCN Guidelines into practice for gynecologic cancer patients.” The MOU signals that the co-creation model piloted in Manila, in which national societies contribute clinical and regulatory insight while NCCN contributes its evidence-review infrastructure, could be replicated wherever professional societies and health ministries are prepared to invest in adaptation.

The scale of NCCN’s existing international footprint gives the Philippine project considerable leverage. There are currently more than 90 international adaptations of the NCCN Guidelines and more than 180 different translations across numerous languages, a library that allows clinicians in widely varying settings to consult recommendations calibrated to their own circumstances. Each adaptation undergoes the same underlying discipline: systematic review of the evidence, expert consensus, and frequent updates as new data emerge, followed by regional modification for feasibility and applicability. Because the Philippine adaptations will be freely accessible online, they have the potential to reach not only specialists in tertiary centers but also the general practitioners and community oncologists who manage the majority of cancer patients in the country.

What emerges from the Montreal and Manila meetings is a picture of cancer care standardization as a genuinely global, collaborative enterprise rather than a one-directional export of American clinical doctrine. The Philippine adaptations, spanning seven disease types with PSMO and three gynecologic cancers with SGOP and IGCS, will test whether locally co-created guidelines can be woven into national policy under the National Integrated Cancer Control Act and sustained through the country’s health programs. If the Polish experience is any guide, the combination of professional society leadership, ministerial support, and an internationally recognized evidence framework can produce measurable improvements in consistency and quality of care. For Filipino patients, the practical promise is concrete: treatment recommendations that reflect both the best available global evidence and the specific realities of the hospitals, regulations, and resources where they are actually treated.

Subject of Research: International adaptation of NCCN clinical practice guidelines for cancer treatment in the Philippines

Article Title: NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia

Article References: NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, cancer guidelines, Philippines, gynecologic oncology, PSMO, IGCS, SGOP, international adaptations, health policy, NICCA, cancer care equity, oncology

The World Cancer Congress, organized every two years by the Union for International Cancer Control, is the flagship international meeting on cancer control. It draws researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries, making it a natural stage for work that sits at the intersection of clinical medicine and public health policy. Representing the network’s Global Policy team in Hong Kong are Matt Izzo, MPP, Senior Specialist for Global Policy and Strategic Alliances, and Stephanie Montesino, MPH, a Global Policy and Advocacy Fellow, each presenting one of the two abstracts. The organization also maintains an informational booth at the congress where attendees can learn about its international programs and collect free patient resources.

Crystal S. Denlinger, MD, Chief Executive Officer of the network, framed the stakes in a statement released ahead of the meeting. The congress, she said, offers a unique opportunity to engage with key decision-makers worldwide regarding cancer care and policy. Everyone, she argued, should have access to the best possible cancer prevention and treatment regardless of where they are located, and she expressed pride in sharing what the network and its in-country collaborators are doing to improve cancer outcomes around the globe while working with others to build on that success. That framing matters, because the two abstracts presented in Hong Kong are not merely academic exercises; they are evidence for a policy argument that regionally appropriate guidelines belong at the center of national cancer planning.

The first abstract, titled “The Inclusion of Clinical Practice Guidelines in National Cancer Control Plans,” examines a class of documents that most people outside health ministries have never heard of but that shape care for millions. National Cancer Control Plans are government-led public health initiatives that lay out clearly defined processes for cancer prevention, screening, and treatment. They are, in effect, a country’s master blueprint for reducing its cancer burden. The research team’s findings offer both encouragement and a warning. On the encouraging side, 61 percent of active national cancer control plans include references to existing national or international cancer treatment guidelines, and another 19 percent include strategies for developing such guidelines. Taken together, that means roughly four in five plans at least acknowledge the role of structured clinical guidance.

The warning lies in the details. While the vast majority of the plans studied, 86 percent, feature strategies for implementing the use of guidelines more broadly, most of them overlook the systems needed to measure whether that implementation actually happens, and whether it happens equitably and with quality. A plan that tells clinicians to follow guidelines but never checks whether they do, or whether patients in rural and underserved regions receive the same standard of care as those in major cities, leaves the hardest part of the work undone. The research also identified significant room for growth in incorporating guidance on disease staging, the systematic classification of how far a cancer has progressed. Staging is critical for identifying population-level trends and for designing targeted interventions, yet it remains underdeveloped in many national plans.

The second abstract shifts from policy documents to clinical practice. Titled “Enhancing Nasopharyngeal Carcinoma Care in China Through Adapted Clinical Guidelines,” it was authored jointly with Dr. Jun Ma and Dr. Ying Sun, both Chief Physicians and Radiation Oncologists at Sun Yat-sen University Cancer Center in Guangzhou, China. The abstract explains how the network worked with local experts in China to create the Chinese Editorial Committee, a body that then adapted the network’s Clinical Practice Guidelines in Oncology for Head and Neck Cancers into a dedicated Chinese edition covering cancer of the nasopharynx. The goal was to tailor recommendations to regional clinical practice and resource availability, producing a practical, context-specific framework for elevating the management of nasopharyngeal cancers across diverse clinical settings in China.

The choice of nasopharyngeal carcinoma is not incidental. Dr. Ma, in comments provided with the release, noted that the disease is substantially more common in China than in the United States, reflecting a combination of Epstein-Barr virus-related, genetic, and environmental factors. That higher disease burden has generated extensive local clinical experience and, in places, meaningful differences in practice compared with American norms. Local experts were therefore able to suggest several adaptations to the original guidelines based on clinical data from China. These included the addition of medications that are available in China but not necessarily elsewhere, as well as the expansion of some systemic therapy and radiation therapy recommendations. The result, Dr. Ma said, is a set of guidelines built on the network’s time-tested methods but optimized for people in China, and he described the underlying guidelines as the gold standard, shown to improve the quality, effectiveness, equitability, and accessibility of cancer care around the world.

The scale of the adaptation effort is considerable. Nearly half of all registered users of the network’s guidelines are international professionals, with the largest concentrations in China, India, South Korea, Brazil, Mexico, Japan, Thailand, Canada, Spain, and Italy. Across the globe there are now more than 90 international adaptations of the guidelines and more than 180 different translations in numerous languages. Those numbers describe something rare in medicine: a single, continuously updated evidence framework that is simultaneously authoritative enough to anchor practice in Boston or Houston and flexible enough to be reworked for the drug formularies, diagnostic capacity, and epidemiology of Guangzhou or Mexico City. All of the organization’s global cancer resources are available for free through its website or its Virtual Library mobile app.

What emerges from the two abstracts is a coherent model. On one side, the analysis of national cancer control plans shows that governments are already reaching for clinical guidelines but frequently stop short of the measurement and staging infrastructure that turns a written recommendation into measurable, equitable care. On the other side, the China collaboration demonstrates what disciplined adaptation looks like: a standing editorial committee of local experts, a defined process for incorporating region-specific clinical data and drug availability, and a commitment to preserving the evidence-based methodology of the original while adjusting its content. Presented together at a congress attended by policymakers from more than 120 countries, the two pieces of research make a case that could reshape how the next generation of national cancer plans is written, with guidelines that are not just referenced but implemented, measured, and honestly tailored to the populations they are meant to serve.

Subject of Research: Adapting clinical practice guidelines for regional cancer care and national cancer control planning

Article Title: NCCN models how to tailor cancer care for different regions during 2026 World Cancer Congress

Article References: NCCN models how to tailor cancer care for different regions during 2026 World Cancer Congress. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, World Cancer Congress, national cancer control plans, clinical practice guidelines, nasopharyngeal carcinoma, China, UICC, global health policy, guideline adaptation, cancer care equity, Sun Yat-sen University Cancer Center, head and neck cancers